Delivery of myelin protein or peptide sequences, mainly based on myelin basic protein (MBP), by different administration routes (9, 10), as DNA vaccines (11), or in altered forms (12, 13), all showed encouraging results in animal models, but did not perform well in clinical studies in MS patients. The gene discussed is MBP; the disease is myeloid sarcoma.